Analysts Set Immuneering Corporation (NASDAQ:IMRX) Price Target at $17.57

Shares of Immuneering Corporation (NASDAQ:IMRX) have earned an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $17.5714.

Several research firms have recently commented on IMRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research report on Wednesday, June 24th. Needham & Company LLC boosted their price objective on Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Chardan Capital restated a “buy” rating and set a $20.00 target price on shares of Immuneering in a research report on Tuesday, May 19th. Oppenheimer reissued an “outperform” rating on shares of Immuneering in a research note on Monday, June 1st. Finally, Cantor Fitzgerald initiated coverage on shares of Immuneering in a research note on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 price objective for the company.

Institutional Trading of Immuneering

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMRX. Geode Capital Management LLC increased its stake in Immuneering by 2.0% in the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after purchasing an additional 4,458 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Immuneering in the 4th quarter worth approximately $33,000. Southport Management L.L.C. lifted its holdings in Immuneering by 1.8% during the fourth quarter. Southport Management L.L.C. now owns 277,501 shares of the company’s stock worth $1,826,000 after buying an additional 5,000 shares during the period. Dimensional Fund Advisors LP boosted its position in Immuneering by 46.4% during the third quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company’s stock valued at $137,000 after purchasing an additional 6,196 shares in the last quarter. Finally, LPL Financial LLC boosted its holdings in shares of Immuneering by 30.0% in the 4th quarter. LPL Financial LLC now owns 29,125 shares of the company’s stock valued at $192,000 after buying an additional 6,725 shares in the last quarter. 67.65% of the stock is owned by hedge funds and other institutional investors.

Immuneering Price Performance

Immuneering stock opened at $4.23 on Friday. The business’s fifty day moving average is $4.69 and its 200 day moving average is $4.99. The stock has a market capitalization of $273.68 million, a PE ratio of -3.62 and a beta of 0.41. Immuneering has a one year low of $2.90 and a one year high of $10.08.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.09. As a group, sell-side analysts expect that Immuneering will post -1.09 EPS for the current fiscal year.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.